drugset / Trial / NCT05093140
Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL
NaSingle-groupOpen-labelTreatment
Summary
To assess the efficacy and safety of camrelizumab combined with rituximab, vincristine, doxorubicin, cyclophosphamide and prednisone in the treatment of untreated primary extranodal DLBCL
Timeline
- Start
- 2022-06-01
- Primary completion
- 2023-06
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 60 mg/m2 | Oral |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | Intravenous |
| Background | hydroxyldaunorubicin | Unknown | 50 mg/m2 | Intravenous |